| scholarly article | Q13442814 |
| P50 | author | David Tan | Q58821394 |
| P2093 | author name string | Joline S J Lim | |
| P2860 | cites work | The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway | Q22065419 |
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study | Q27853070 | ||
| DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer | Q27853235 | ||
| Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy | Q27860519 | ||
| 53BP1 regulates DSB repair using Rif1 to control 5' end resection | Q28000120 | ||
| Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase | Q28131711 | ||
| A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency | Q28256846 | ||
| The concept of synthetic lethality in the context of anticancer therapy | Q28268061 | ||
| Resistance to therapy caused by intragenic deletion in BRCA2 | Q28268169 | ||
| Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching | Q29465549 | ||
| Systematic identification of genomic markers of drug sensitivity in cancer cells | Q29547695 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models | Q52811875 | ||
| Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial | Q53668957 | ||
| PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. | Q55004657 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| (ADP-ribose)n participates in DNA excision repair | Q59086284 | ||
| Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors | Q59273887 | ||
| Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer | Q83145997 | ||
| Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer | Q37743501 | ||
| "Contextual" synthetic lethality and/or loss of heterozygosity: tumor hypoxia and modification of DNA repair. | Q37786125 | ||
| P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. | Q38078058 | ||
| Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways | Q38091054 | ||
| ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development | Q38107993 | ||
| Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. | Q38387666 | ||
| Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors | Q38848720 | ||
| Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. | Q38991113 | ||
| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. | Q39138428 | ||
| PARP inhibitors: Synthetic lethality in the clinic | Q39182835 | ||
| Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors | Q39252597 | ||
| Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation | Q39348799 | ||
| Radiosensitization effect of poly(ADP‐ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation | Q39382732 | ||
| The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy | Q39515166 | ||
| Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval | Q39712677 | ||
| Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. | Q41279772 | ||
| CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. | Q41466400 | ||
| Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer | Q41475235 | ||
| Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study | Q44846367 | ||
| Turning ecology and evolution against cancer | Q46904792 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial | Q30080035 | ||
| Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy | Q33418574 | ||
| Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma | Q33424674 | ||
| Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer | Q33435836 | ||
| Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non-Small Cell Lung Cancer | Q33436465 | ||
| A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours | Q33439527 | ||
| Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers | Q33439705 | ||
| Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | Q33944203 | ||
| Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer | Q34287982 | ||
| Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors | Q34309488 | ||
| Role of poly(ADP-ribose) formation in DNA repair | Q34359946 | ||
| RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. | Q34366919 | ||
| Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. | Q34422265 | ||
| Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors | Q35142790 | ||
| ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors | Q35836542 | ||
| Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. | Q35845827 | ||
| BRCA1 Functions Independently of Homologous Recombination in DNA Interstrand Crosslink Repair | Q35923364 | ||
| Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. | Q35950459 | ||
| The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin | Q36326279 | ||
| A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study | Q36483833 | ||
| Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma | Q36755432 | ||
| mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer | Q36874139 | ||
| Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer | Q36941966 | ||
| Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers | Q36958682 | ||
| PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response | Q36962771 | ||
| Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer | Q37069878 | ||
| Regulation of DNA repair throughout the cell cycle | Q37088926 | ||
| CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer | Q37173597 | ||
| Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model | Q37217995 | ||
| PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition | Q37445131 | ||
| Exploiting ecological principles to better understand cancer progression and treatment. | Q37561441 | ||
| Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness | Q37584321 | ||
| Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib | Q37623863 | ||
| Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. | Q37634102 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P577 | publication date | 2017-08-22 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors | |
| P478 | volume | 9 |
| Q64232953 | Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment |
| Q92399372 | DNA Repair: Translation to the Clinic |
| Q48124146 | Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells |
| Q65002852 | Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma. |
| Q92310629 | PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target |
| Q52628817 | Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors? |
| Q55438200 | Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. |
| Q42364707 | The Impact of DNA Repair Pathways in Cancer Biology and Therapy |
Search more.